ABX
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
📊 Snapshot
Ticker
ABX
Company
Abacus Global
Sector
Insurance
Market Cap
$842M
Current Price
$8.52
52W High/Low
$12.44 / $5.00
YTD Return
+34.60%
Dividend Yield
2.35%
📈 Earnings Momentum
Data Coverage Note: Detailed quarterly earnings history unavailable. Analysis based on trailing metrics.
| Metric | Value | Assessment |
|---|---|---|
| TTM EPS (Actual) | $0.395 | Based on last reported metric |
| Revenue Growth YoY | +86.13% | Exceptional top-line expansion |
| Forward P/E | 9.69x | Implies forward EPS ~$0.88 (12-month forward) |
| EPS Growth YoY | Not disclosed | Implied forward growth ~122% based on forward P/E compression |
| Earnings Date | Not disclosed | Limited visibility on next earnings event |
Earnings Momentum Score: 6.2/10 — Strong revenue growth (+86% YoY) signals robust top-line momentum. Forward P/E of 9.69x vs. trailing 23.05x suggests significant implied earnings growth expectations. However, lack of detailed quarterly trends and forward guidance limits conviction. Recent quarter-over-quarter trends unavailable.
💰 Profitability & Quality
Data Coverage Note: Income statement detail, margins, and cash flow not disclosed in current dataset.
| Metric | Value | Implication |
|---|---|---|
| Gross Margin | Not disclosed | Insurance business model; margin data typically proprietary |
| Operating Margin | Not disclosed | Coverage constrained |
| Net Margin | Not disclosed | Implied from EPS: ~4.6% (on est. revenue base) |
| EPS Metric | $0.395 | Small absolute earnings; modest profitability on micro-cap base |
| Free Cash Flow | Not disclosed | No FCF data; insurance business model may not report traditional FCF |
| Quality Flags | Hyper-growth Not high-valuation | Growth-stage company; profitability not flagged as strong |
Quality Score: 3.5/10 — Limited profitability data disclosed. Insurance sector obscures traditional margin metrics. Revenue growth is exceptional, but profitability quality not confirmed. Small EPS base ($0.395) and absence of FCF data suggest early-stage business or limited scale. Risk of earnings volatility in emerging insurer.
🛡️ Balance Sheet Health
Data Coverage Note: Balance sheet detail not available in current dataset. Structural assessment limited.
| Metric | Value | Status |
|---|---|---|
| Cash & Equivalents | Not disclosed | Limited visibility |
| Total Debt | Not disclosed | Limited visibility |
| Net Debt / EBITDA | Not disclosed | Assessment not possible |
| Current Ratio | Not disclosed | Liquidity structure unknown |
| Risk Flags | Weak balance flagged: No | System does not indicate balance sheet stress, but data sparse |
| Business Risk | Micro-cap insurance startup | Elevated structural leverage risk for emergent insurer |
Balance Sheet Risk: MODERATE-HIGH — Detailed financial structure not disclosed. As an early-stage insurance company on a micro-cap base ($842M market cap), balance sheet stress is a latent risk. No explicit weak-balance flag in system, but absence of data itself constitutes a yellow flag for institutional investors. Recommend requesting 10-K filing directly for debt, capital adequacy, reserve ratios.
💎 Valuation Analysis
| Metric | ABX | Assessment |
|---|---|---|
| Trailing P/E | 23.05x | Above-market for insurance; elevated for micro-cap |
| Forward P/E | 9.69x | Deep compression; implies strong forward earnings growth |
| PEG Ratio | ~0.12x | Highly attractive if 86% revenue growth converts to earnings |
| Price / Sales | Est. ~1.4x (est.) | Moderate valuation on sales basis |
| EV / EBITDA | Not calculated (no EBITDA data) | Coverage constrained |
| Enterprise Value | $841.99M | Roughly equals market cap (minimal net debt visibility) |
| 52W Return | +34.60% | Substantial YTD re-rating; valuation has expanded |
Valuation Status: FAIRLY VALUED (MOMENTUM-DRIVEN) — Trailing P/E of 23x is expensive in absolute terms, but forward P/E of 9.69x and PEG <0.15x suggest the market is pricing in powerful earnings leverage. Stock has rallied +34.6% YTD, suggesting re-rating has already occurred. Valuation is fair IF revenue growth (86% YoY) translates into near-doubling of earnings. Downside risk if growth disappoints.
🎯 Analyst Targets & Sentiment
Data Coverage Note: Consensus target price, analyst ratings, and dispersion not available in current dataset.
| Metric | Value | Implication |
|---|---|---|
| Target Price (Mean) | Not disclosed | Analyst consensus unavailable |
| Implied Upside / Downside | Not calculable | Assessment limited |
| Rating Distribution | Not available | Buy/Hold/Sell split unknown |
| Coverage Breadth | Sparse for micro-cap | Typical for $842M market cap insurer; limited Street coverage expected |
| Recent Momentum | +34.6% YTD | Retail/momentum driven likely; limited institutional initiation |
Wall Street Sentiment: NEUTRAL (LIMITED VISIBILITY) — No consensus target or analyst ratings available, which is typical for micro-cap specialty insurers. The absence of Street coverage is itself a sentiment signal: limited institutional interest. Stock performance (+34.6% YTD) appears momentum/retail-driven rather than fundamentals-driven analyst upgrade cycle. Recommendation: Contact investor relations for target and guidance directly.
🔍 Institutional & Risk Check
| Risk Factor | Status | Notes |
|---|---|---|
| Institutional Ownership | Not disclosed | Typical low institutional ownership for micro-cap insurer |
| Insider Ownership | Not disclosed | Data not available; recommend 10-K review |
| Short Interest | Not disclosed | Assessment limited |
| Dividend Sustainability | 2.35% yield | $0.2054/share DPS; payout ratio ~52% based on EPS — moderate |
| Beta (Volatility) | 0.022 | Extremely low beta; suggests limited market correlation or illiquid stock |
| Avg. Volume | 630.64K shares | Illiquidity risk for large positions; wide bid-ask spreads likely |
| Profitability Flag | Strong profitability: No | Earnings quality and sustainability not confirmed |
Risk Level: ELEVATED — Micro-cap ($842M) specialty insurer with extreme illiquidity (avg volume 630K shares), negligible beta (0.022 — likely a data artifact or illiquidity signal), no analyst coverage, and unconfirmed earnings quality. Dividend is sustainable at current levels (52% payout ratio) but vulnerable to earnings miss. High execution risk on 86% revenue growth expectation. Recommend: position sizing <2% portfolio weight; use limit orders only; request Form 4 filings and recent 10-K before investing.
🎖️ ESEN FINAL VERDICT
52
/ 100 Fundamental Score
MODERATE CONVICTION
Short Term (1–3M)
HOLD
Medium Term (6–12M)
ACCUMULATE
Long Term (2Y+)
SELECTIVE BUY
- Growth Tailwind: 86% YoY revenue growth and forward P/E compression (9.69x) signal powerful earnings leverage IF top-line expansion converts to bottom-line profits. PEG <0.15x is exceptionally attractive.
- Quality Gaps: Limited financial disclosures (no margins, FCF, balance sheet detail). Early-stage insurer with unproven profitability durability. Earnings quality flagged as "not strong" by system.
- Valuation Fair but Momentum-Driven: +34.6% YTD return suggests re-rating already priced in. Stock has rallied on growth narrative; downside risk if guidance disappoints or macro insurance headwinds emerge.
- Illiquidity Red Flag: Micro-cap ($842M) with ultra-low volume (630K shares/day) and negligible beta. Institutional adoption remains minimal. Position sizing critical.
- Action Plan: HOLD current positions; SELECTIVE ACCUMULATION on any Q2/Q3 earnings miss (entry opportunity). Require 10-K review, capital adequacy analysis, and detailed margins before significant allocation. Monitor next earnings call closely for guidance and reserve adequacy trends.
AI STOCK INSIGHT
ABX Stock Analysis & Forecast
Is ABX a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
ABX Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, ABX shows balanced risk-reward characteristics.
Should You Buy ABX Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in ABX.